Version 5.2 of WAPPS-Hemo introduces a large set of minor incremental updates, many on the back-end, to make our human validation more efficient, many in the connectivity to external software and applications, and many to the look and general functionalities.
For WAPPS-Hemo users located in Europe, McMaster is excited to announce the launch of McMaster PopPK. If you see value in using a CE-marked platform, then McMaster PopPK is now available for you. This new CE-marked platform provides individual pharmacokinetic parameters based on the trusted WAPPS-Hemo engine. McMaster PopPK is CE-marked as an in vitro diagnostic device class I in accordance with the EU IVD Directive. McMaster PopPK supports myWAPPS and florioTM to display estimated factor levels via patient smartphone apps.
WAPPS-Hemo is pleased to announce the launch of two new population pharmacokinetic (PK) models for ESPEROCT® (Antihemophilic Factor VIII (Recombinant, B-Domain Truncated), PEGylated) that use the one-stage and chromogenic assays.
Looking for an opportunity to participate in a clinical trial for WAPPS? There are currently two trials that are recruiting.
Currently available PK models in WAPPS-Hemo. New models are added when sufficient data has been collected.
At WAPPS-News we post the latest updates and changes to the WAPPS-Hemo program. Check back with us regularly. Contact us if you have any questions.
The WAPPS-HEMO Team
If you have any WAPPS-Hemo related research or news items you would like to share, please contact us
© 2023 Copyright WAPPS-Hemo